161 related articles for article (PubMed ID: 16203654)
1. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
3. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Nielsen T; Christiansen C
Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
[TBL] [Abstract][Full Text] [Related]
6. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
7. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
9. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
[TBL] [Abstract][Full Text] [Related]
12. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
Gargano V; Massaro M; Morra I; Formisano C; Di Carlo C; Nappi C
Contraception; 2008 Jul; 78(1):10-5. PubMed ID: 18555812
[TBL] [Abstract][Full Text] [Related]
13. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
Palacios S; Foidart JM; Genazzani AR
Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
[TBL] [Abstract][Full Text] [Related]
14. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
Tankó LB; Christiansen C
J Intern Med; 2005 Dec; 258(6):544-53. PubMed ID: 16313478
[TBL] [Abstract][Full Text] [Related]
15. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
Ettinger B; Ensrud KE; Wallace R; Johnson KC; Cummings SR; Yankov V; Vittinghoff E; Grady D
Obstet Gynecol; 2004 Sep; 104(3):443-51. PubMed ID: 15339752
[TBL] [Abstract][Full Text] [Related]
16. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
Nappi C; Di Spiezio Sardo A; Greco E; Tommaselli GA; Giordano E; Guida M
Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone in HRT?
Drug Ther Bull; 2009 Apr; 47(4):41-4. PubMed ID: 19357298
[TBL] [Abstract][Full Text] [Related]
18. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.
Ravn P; Warming L; Christgau S; Christiansen C
Bone; 2004 Nov; 35(5):1216-21. PubMed ID: 15542048
[TBL] [Abstract][Full Text] [Related]
19. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
[TBL] [Abstract][Full Text] [Related]
20. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]